Open Label, Dose Escalation Phase I Study of AZD2281

Phase 1 Completed 18 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies

Timeline

Start: 2007-11
Primary completion: 2009-03
Completion: 2009-06

Publications

Yamamoto N, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, Yamada K, Asahina H, Kawata T, Shi X, Tamura T. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci. 2012 Mar;103(3):504-9. doi: 10.1111/j.1349-7006.2011.02179.x. Epub 2012 Jan 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olaparib	Small molecule	100 mg	Oral
Subject	Olaparib	Small molecule	200 mg	Oral
Subject	Olaparib	Small molecule	400 mg	Oral

Open Label, Dose Escalation Phase I Study of AZD2281

Summary

Timeline

Publications

Drugs

Indications